Holger Woehrle.

The primary analysis was conducted in the intention-to-treat population, which contains all of the patients who underwent randomization, with adjudication of all events that occurred prior to the data source was locked. The significance level of the final analysis step was 0.024, keeping an overall two-sided significance level of 5 percent. The surplus of occasions at the termination of the trial was included in the final evaluation with the use of the inverse normal method . Cause-particular hazard ratios were calculated, and cumulative incidence curves that may take potential competing risks into account were used to visualize survival data.Furthermore, the different designations lately granted by the FDA in both indications and the EMA’s positive Scientific Tips for multiple myeloma, will accelerate in addition to facilitate the future review and marketing authorization processes in THE UNITED STATES and Europe.’ Related StoriesCornell biomedical engineers develop 'super organic killer cells' to destroy cancers cells in lymph nodesViralytics enters into scientific trial collaboration contract with MSDMeat-rich diet plan may increase kidney cancer riskDennis Turpin, Senior Vice Chief and President Financial Officer of Aeterna Zentaris added, ‘With an increase of than $40 million in cash, including proceeds from our recent $15 million registered direct offering and no debt, coupled with our expected decreased burn rate significantly, we are in a good financial position to execute our focused drug business and development strategy.’ CONSOLIDATED RESULTS FOR THE 90 DAYS ENDED MARCH 31, 2010 Revenues were $6.4 million for the three-month period ended March 31, 2010, in comparison to $6.1 million for the same period in ’09 2009.